CEACAM5 and lung carcinoma: In this work, we proposed a multi-biomarker panel (4MP) combining pro-surfactant protein B (Pro-SFTPB), carbohydrate antigen 125 (CA125), cytokeratin 19 fragmentCyfra21-1, and CEA to distinguish lung cancer from benign lung disease in 294 patients.